Cantor Fitzgerald Analysts Cut Earnings Estimates for Omeros

Omeros Co. (NASDAQ:OMER) – Research analysts at Cantor Fitzgerald decreased their FY2025 earnings estimates for shares of Omeros in a research note issued on Wednesday, April 2nd. Cantor Fitzgerald analyst O. Brayer now forecasts that the biopharmaceutical company will post earnings per share of ($2.19) for the year, down from their prior forecast of ($1.73). The consensus estimate for Omeros’ current full-year earnings is ($3.09) per share. Cantor Fitzgerald also issued estimates for Omeros’ FY2025 earnings at ($2.19) EPS.

Several other equities analysts have also issued reports on OMER. Needham & Company LLC restated a “hold” rating on shares of Omeros in a research report on Tuesday. D. Boral Capital restated a “buy” rating and issued a $36.00 target price on shares of Omeros in a report on Tuesday. Finally, StockNews.com upgraded shares of Omeros from a “sell” rating to a “hold” rating in a report on Tuesday. Three analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Omeros has a consensus rating of “Moderate Buy” and a consensus target price of $22.50.

Omeros Trading Down 4.1 %

Shares of NASDAQ:OMER opened at $7.06 on Friday. The stock has a market capitalization of $409.93 million, a P/E ratio of -3.06 and a beta of 2.35. The stock’s 50-day moving average price is $8.56 and its 200-day moving average price is $7.63. Omeros has a 12-month low of $2.97 and a 12-month high of $13.60.

Institutional Investors Weigh In On Omeros

Several institutional investors and hedge funds have recently bought and sold shares of the business. Charles Schwab Investment Management Inc. boosted its holdings in Omeros by 4.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 485,035 shares of the biopharmaceutical company’s stock valued at $1,926,000 after acquiring an additional 18,454 shares in the last quarter. BNP Paribas Financial Markets increased its position in shares of Omeros by 130.6% during the third quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 7,016 shares during the period. HighTower Advisors LLC raised its stake in Omeros by 7.2% in the third quarter. HighTower Advisors LLC now owns 59,339 shares of the biopharmaceutical company’s stock worth $235,000 after buying an additional 4,000 shares in the last quarter. State Street Corp lifted its holdings in Omeros by 0.3% in the third quarter. State Street Corp now owns 1,226,053 shares of the biopharmaceutical company’s stock worth $4,867,000 after buying an additional 3,839 shares during the period. Finally, Wellington Management Group LLP bought a new stake in Omeros during the 3rd quarter valued at approximately $305,000. Hedge funds and other institutional investors own 48.79% of the company’s stock.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.